[144] Arteris, Inc. SEC Filing

Rhea-AI Filing Summary

Arteris, Inc. (AIP) filed a Form 144 reporting a proposed Rule 144 sale of 100,000 common shares through Morgan Stanley Smith Barney LLC on the 10/06/2025, with an aggregate market value of $1,098,000.00 based on the filing. The shares were acquired in a private issuance from the issuer on 11/05/2013 and the filing says payment was made by check on that date.

The filing also discloses multiple sales by the same person (and related 10b5-1 plans) during the past three months, including a 94,245-share 10b5-1 sale on 08/05/2025 and other transactions totaling material proceeds. The filer attests they have no undisclosed material adverse information.

Insights

Equity Capital Markets Analyst

Existing insider plans are being executed; 100,000 shares now planned for sale.

The filing shows a proposed Rule 144 sale of 100,000 common shares with an aggregate market value of $1,098,000.00 to be executed via Morgan Stanley Smith Barney LLC on 10/06/2025. The shares were acquired in a private issuance on 11/05/2013, indicating these are older, restricted-origin shares now eligible for sale under Rule 144.

Recent dispositions include multiple 10b5-1 and open-market sales across 08/05/2025–10/03/2025, producing material gross proceeds in some trades. Monitor short-term share supply changes and daily trading volume around 10/06/2025 for any transient price pressure.

Corporate Governance Specialist

Sales follow written plans and include 10b5-1 executions; signer attests no undisclosed material info.

The filing records both 10b5-1 plan sales and direct sales by the named person, including a large 10b5-1 sale of 94,245 shares on 08/05/2025. The notice contains the statutory attestation that the seller has no undisclosed material adverse information as of the plan adoption or instruction date.

Because multiple scheduled sales occurred recently, stakeholders should note the ongoing execution of planned insider liquidity events rather than ad-hoc disposals; check company disclosures for any contemporaneous announcements if correlation with corporate events is a concern.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	100000	1098000.00	42649917	10/06/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	11/05/2013	Private Acquisition from Issuer or an Affiliate	Issuer			100000	11/05/2013	Check

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
10b5-1 Sales for K. CHARLES JANAC 900 E. Hamilton Ave., Suite 300 Campbell CA 95008	Common	10/03/2025	11821	130864.34
K. CHARLES JANAC 900 E. Hamilton Ave., Suite 300 Campbell CA 95008	Common	10/02/2025	7147	78050.96
10b5-1 Sales for K. CHARLES JANAC 900 E. Hamilton Ave., Suite 300 Campbell CA 95008	Common	09/04/2025	2057	17948.35
K. CHARLES JANAC 900 E. Hamilton Ave., Suite 300 Campbell CA 95008	Common	09/02/2025	1246	1552516.00
10b5-1 Sales for K. CHARLES JANAC 900 E. Hamilton Ave., Suite 300 Campbell CA 95008	Common	08/05/2025	94245	1271120.01
10b5-1 Sales for BAYVIEW LEGACY, LLC 900 E. Hamilton Ave., Suite 300 Campbell CA 95008	Common	08/05/2025	50000	655995.00

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does Arteris (AIP) report in this Form 144?

The filing reports a proposed sale of 100,000 common shares through Morgan Stanley Smith Barney LLC on 10/06/2025 with an aggregate market value of $1,098,000.00.

When and how were the shares being sold acquired?

The 100,000 shares were acquired in a private issuance from the issuer on 11/05/2013 and payment was made by check on that date.

Has the filer sold other Arteris shares recently?

Yes. The filing lists multiple sales from 08/05/2025 to 10/03/2025, including a 94,245-share 10b5-1 sale on 08/05/2025.

What is the filer’s attestation about material information?

By signing, the person represents they do not know any material adverse information about the issuer that has not been publicly disclosed as of the plan adoption or instruction date.

Through which broker will the proposed sale be executed?

The proposed sale is to be executed through Morgan Stanley Smith Barney LLC, located at 1 New York Plaza, 8th Floor, New York, NY.